Martijn B. Katan
Research Subjects
Research Interests
Martijn B. Katan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Ingeborg A. Brouwer
Department of Health Sciences, Faculty of Science, Amsterdam Public Health Research Institute, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, the Netherlands
2 shared publications B Vessby
Department of Public Health and Caring Sciences/Clinical Nutrition Research, University of Uppsala, Uppsala, Sweden
1 shared publication- Carolien Vink
TI Food and Nutrition, Wageningen, The Netherlands
1 shared publication - David S. Ludwig
New Balance Foundation Obesity Prevention Center, Boston Children’s Hospital, Boston, USA
1 shared publication - Evelien Kramer
RIKILT – Wageningen University & Research Centre, 6700 AE Wageningen, The Netherlands
1 shared publication - Ingeborg M. J. Bovee-Oudenhoven
TI Food and Nutrition, Wageningen, The Netherlands
1 shared publication
Latest Publications
- 1 January 2013
- Vol. 157 (22) , A6290
[Linoleic acid and heart infarct].
A re-analysis of the Sydney Diet Heart Study (Ramsden et al., BMJ 2013) suggested that a diet high in linoleic acid increased the risk of coronary heart disease. The authors ascribe this to a lack of the omega-3 fatty acid, alpha-linolenic acid, in the oils and fats consumed. This argument has some weaknesses. Mortality in the linoleic acid group was 38 cases versus 27 in the control group (or 35 versus 28, or 39 versus 28; sources differ). The difference was significant in the current, though not in the original, publication. Conceivably, application of multiple statistical models led to chance significances. Additionally, the fats consumed by subjects in the intervention group were high in trans fats, which may have increased risk. Finally, a large recent clinical trial failed to show any benefit of linolenic acid. The conclusion is, therefore, that this re-analysis provides insufficient evidence to justify changes in current dietary recommendations.
- 1 January 2013
- Vol. 157 (22) , A6290
[Linoleic acid and heart infarct].
A re-analysis of the Sydney Diet Heart Study (Ramsden et al., BMJ 2013) suggested that a diet high in linoleic acid increased the risk of coronary heart disease. The authors ascribe this to a lack of the omega-3 fatty acid, alpha-linolenic acid, in the oils and fats consumed. This argument has some weaknesses. Mortality in the linoleic acid group was 38 cases versus 27 in the control group (or 35 versus 28, or 39 versus 28; sources differ). The difference was significant in the current, though not in the original, publication. Conceivably, application of multiple statistical models led to chance significances. Additionally, the fats consumed by subjects in the intervention group were high in trans fats, which may have increased risk. Finally, a large recent clinical trial failed to show any benefit of linolenic acid. The conclusion is, therefore, that this re-analysis provides insufficient evidence to justify changes in current dietary recommendations.
- 1 January 2013
- Vol. 157 (24) , A6471
[Health claims for medical foods].
Souvenaid (Nutricia, Zoetermeer, the Netherlands) is a medical food for the dietary management of early Alzheimer's disease. The mix of nutrients in this drink is suggested to have a beneficial effect on cognitive function; such implicit health claims for medical foods are not checked by government agencies. Souvenaid has been investigated in three clinical trials. The first trial showed that Souvenaid produced a significant improvement in delayed verbal recall, but not in other psychological tests. The second and largest trial showed no effect on any outcome. The third trial showed no significant effect at 12 or 24 weeks, but a significant difference in the 24-week time course of the composite memory score. None of these outcomes was clearly specified as a primary outcome at trial registration. In conclusion, there is no convincing proof that Souvenaid benefits cognitive function. Better scrutiny of the efficacy of medical foods is warranted.
- 1 January 2013
- Vol. 157 (24) , A6471
[Health claims for medical foods].
Souvenaid (Nutricia, Zoetermeer, the Netherlands) is a medical food for the dietary management of early Alzheimer's disease. The mix of nutrients in this drink is suggested to have a beneficial effect on cognitive function; such implicit health claims for medical foods are not checked by government agencies. Souvenaid has been investigated in three clinical trials. The first trial showed that Souvenaid produced a significant improvement in delayed verbal recall, but not in other psychological tests. The second and largest trial showed no effect on any outcome. The third trial showed no significant effect at 12 or 24 weeks, but a significant difference in the 24-week time course of the composite memory score. None of these outcomes was clearly specified as a primary outcome at trial registration. In conclusion, there is no convincing proof that Souvenaid benefits cognitive function. Better scrutiny of the efficacy of medical foods is warranted.
- 1 June 2012
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 3 (2) , 85-89
Why the European Food Safety Authority was right to reject health claims for probiotics
Probiotics are microbes that are claimed to promote health and well-being when added to foods. However, the European Food Safety Authority (EFSA) has so far advised negatively about health claims for probiotics. Companies and scientists have protested against these rejections, sometimes in vigorous language. I argue that EFSA could not have acted differently, given EU regulations and the lack of convincing evidence for some of the claimed effects of probiotics on human health and well-being. One EU regulation that makes it hard to demonstrate the benefits of probiotics is the prohibition of medical claims, i.e. claims that a food prevents or cures a disease. If this prohibition did not exist, manufacturers of nutritional treatments might circumvent the costly procedures required for drugs, and market their products to ill people without thorough proof that they are effective and safe. However, the prohibition is also a legal fiction, because promotion of health and prevention of disease is largely the same thing. EFSA has recently indicated that it will allow health claims based on the ability of probiotics to reduce infections. To a certain extent, this abolishes the distinction between health claims and medical claims. It remains to be seen if probiotics producers can convince EFSA that their products prevent or cure infections and other diseases in humans.
- 1 June 2012
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. 3 (2) , 85-89
Why the European Food Safety Authority was right to reject health claims for probiotics
Probiotics are microbes that are claimed to promote health and well-being when added to foods. However, the European Food Safety Authority (EFSA) has so far advised negatively about health claims for probiotics. Companies and scientists have protested against these rejections, sometimes in vigorous language. I argue that EFSA could not have acted differently, given EU regulations and the lack of convincing evidence for some of the claimed effects of probiotics on human health and well-being. One EU regulation that makes it hard to demonstrate the benefits of probiotics is the prohibition of medical claims, i.e. claims that a food prevents or cures a disease. If this prohibition did not exist, manufacturers of nutritional treatments might circumvent the costly procedures required for drugs, and market their products to ill people without thorough proof that they are effective and safe. However, the prohibition is also a legal fiction, because promotion of health and prevention of disease is largely the same thing. EFSA has recently indicated that it will allow health claims based on the ability of probiotics to reduce infections. To a certain extent, this abolishes the distinction between health claims and medical claims. It remains to be seen if probiotics producers can convince EFSA that their products prevent or cure infections and other diseases in humans.
- Open Access
- 1 August 2010
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 92 (2) , 459-460
Saturated fat and heart disease
In a meta-analysis of observational studies, Siri-Tarino et al (1) concluded that there was no association of intake of saturated fat with risk of cardiovascula
- 1 August 2010
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 92 (2) , 459-460
Open AccessSaturated fat and heart disease
In a meta-analysis of observational studies, Siri-Tarino et al (1) concluded that there was no association of intake of saturated fat with risk of cardiovascula
- 6 January 2010
- Published by American Medical Association (AMA) in JAMA
- Vol. 303 (1) , 65-66
Extra Calories Cause Weight Gain—But How Much?
How much weight would an individual gain by eating an extra chocolate chip cookie every day for life? One approach to answering this question, frequently used i
- 6 January 2010
- Published by American Medical Association (AMA) in JAMA
- Vol. 303 (1) , 65-66
Extra Calories Cause Weight Gain—But How Much?
How much weight would an individual gain by eating an extra chocolate chip cookie every day for life? One approach to answering this question, frequently used i
- 1 November 2008
- Vol. 152 (44) , 2375-7
[The role of diet in the development of type 2 diabetes mellitus: calories play the leading role].
Diets high in saturated fat, trans fat and glycaemic load and low in fibre and polyunsaturated fat are associated with a 25 to 50% increase in the risk of type 2 diabetes. However, obesity increases this risk by 500 to 1000%. Effects ascribed to dietary composition might therefore be due to unmeasured effects of body size. In clinical trials, a weight loss of 3-5 kg plus twice to min of walking per day reduced the incidence of diabetes by 58%. The size of this effect is remarkable. It points to the solution to the diabetes epidemic, which is to reconstruct cities so as to make people eat less and move more. There is an analogy here with the cholera epidemics, which also could be solved only by changing the urban environment.
- 1 November 2008
- Vol. 152 (44) , 2375-7
[The role of diet in the development of type 2 diabetes mellitus: calories play the leading role].
Diets high in saturated fat, trans fat and glycaemic load and low in fibre and polyunsaturated fat are associated with a 25 to 50% increase in the risk of type 2 diabetes. However, obesity increases this risk by 500 to 1000%. Effects ascribed to dietary composition might therefore be due to unmeasured effects of body size. In clinical trials, a weight loss of 3-5 kg plus twice to min of walking per day reduced the incidence of diabetes by 58%. The size of this effect is remarkable. It points to the solution to the diabetes epidemic, which is to reconstruct cities so as to make people eat less and move more. There is an analogy here with the cholera epidemics, which also could be solved only by changing the urban environment.
- 29 March 2008
- Vol. 152 (13) , 727-30
[The probiotic yogurt Activia shortens intestinal transit, but has not been shown to promote defecation].
Activia is a yogurt product containing the probiotic bacterium Bifidobacterium animalis DN-173 010. Five clinical trials have been carried out. Four of these show that dairy products containing this bacterium shorten intestinal transit in volunteers. However, except in a subgroup of 19 out of 267 patients in one study, no significant effect of Activia was reported on the frequency, quantity or consistency of stools. In its marketing in the Netherlands, the company that produces Activia, Danone, claims that Activia promotes defecation. There is insufficient scientific evidence to support this claim.
- 29 March 2008
- Vol. 152 (13) , 727-30
[The probiotic yogurt Activia shortens intestinal transit, but has not been shown to promote defecation].
Activia is a yogurt product containing the probiotic bacterium Bifidobacterium animalis DN-173 010. Five clinical trials have been carried out. Four of these show that dairy products containing this bacterium shorten intestinal transit in volunteers. However, except in a subgroup of 19 out of 267 patients in one study, no significant effect of Activia was reported on the frequency, quantity or consistency of stools. In its marketing in the Netherlands, the company that produces Activia, Danone, claims that Activia promotes defecation. There is insufficient scientific evidence to support this claim.
- 9 February 2008
- Vol. 152 (6) , 302-7
[Elimination of all trans fatty acids].
At the start of the 20th century, the production of trans fatty acids was originally largely driven by the increasing demand for margarine. The two Dutch margarine firms Van den Bergh and Jurgens played an important role in this early development. In the early 1990s it was shown that trans fatty acids increase the risk of heart disease. Unilever, the successor to Van den Bergh and Jurgens, then took the lead in eliminating trans fatty acids from retail foods worldwide. As a result, intake in The Netherlands fell from 15 g per day in 1980 to 3 g per day in 2003. Dairy products and meat are now the major source of trans fatty acids. The effects on health of these ruminant trans fatty acids are unclear. There are three lessons to be learned from the rise and fall of trans fatty acids. First, a history of safe use does not guarantee safety of food components, because routine surveillance will fail to detect adverse effects on common illnesses with long incubation periods. Second, it shows that it is more effective and easier to change the composition of foods than to change consumer behaviour. And third, governments can have a major impact on consumers' health by mandating the use of healthier food ingredients.
- 9 February 2008
- Vol. 152 (6) , 302-7
[Elimination of all trans fatty acids].
At the start of the 20th century, the production of trans fatty acids was originally largely driven by the increasing demand for margarine. The two Dutch margarine firms Van den Bergh and Jurgens played an important role in this early development. In the early 1990s it was shown that trans fatty acids increase the risk of heart disease. Unilever, the successor to Van den Bergh and Jurgens, then took the lead in eliminating trans fatty acids from retail foods worldwide. As a result, intake in The Netherlands fell from 15 g per day in 1980 to 3 g per day in 2003. Dairy products and meat are now the major source of trans fatty acids. The effects on health of these ruminant trans fatty acids are unclear. There are three lessons to be learned from the rise and fall of trans fatty acids. First, a history of safe use does not guarantee safety of food components, because routine surveillance will fail to detect adverse effects on common illnesses with long incubation periods. Second, it shows that it is more effective and easier to change the composition of foods than to change consumer behaviour. And third, governments can have a major impact on consumers' health by mandating the use of healthier food ingredients.
- 10 October 2007
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 63 (1) , 2-10
Which are the greatest recent discoveries and the greatest future challenges in nutrition?
Background: Nutrition science aims to create new knowledge, but scientists rarely sit back to reflect on what nutrition research has achieved in recent decades. Methods: We report the outcome of a 1-day symposium at which the audience was asked to vote on the greatest discoveries in nutrition since 1976 and on the greatest challenges for the coming 30 years. Most of the 128 participants were Dutch scientists working in nutrition or related biomedical and public health fields. Candidate discoveries and challenges were nominated by five invited speakers and by members of the audience. Ballot forms were then prepared on which participants selected one discovery and one challenge. Results: A total of 15 discoveries and 14 challenges were nominated. The audience elected Folic acid prevents birth defects as the greatest discovery in nutrition science since 1976. Controlling obesity and insulin resistance through activity and diet was elected as the greatest challenge for the coming 30 years. This selection was probably biased by the interests and knowledge of the speakers and the audience. For the present review, we therefore added 12 discoveries from the period 1976 to 2006 that we judged worthy of consideration, but that had not been nominated at the meeting. Conclusions: The meeting did not represent an objective selection process, but it did demonstrate that the past 30 years have yielded major new discoveries in nutrition and health.
- 10 October 2007
- Published by Springer Nature in European Journal of Clinical Nutrition
- Vol. 63 (1) , 2-10
Which are the greatest recent discoveries and the greatest future challenges in nutrition?
Background: Nutrition science aims to create new knowledge, but scientists rarely sit back to reflect on what nutrition research has achieved in recent decades. Methods: We report the outcome of a 1-day symposium at which the audience was asked to vote on the greatest discoveries in nutrition since 1976 and on the greatest challenges for the coming 30 years. Most of the 128 participants were Dutch scientists working in nutrition or related biomedical and public health fields. Candidate discoveries and challenges were nominated by five invited speakers and by members of the audience. Ballot forms were then prepared on which participants selected one discovery and one challenge. Results: A total of 15 discoveries and 14 challenges were nominated. The audience elected Folic acid prevents birth defects as the greatest discovery in nutrition science since 1976. Controlling obesity and insulin resistance through activity and diet was elected as the greatest challenge for the coming 30 years. This selection was probably biased by the interests and knowledge of the speakers and the audience. For the present review, we therefore added 12 discoveries from the period 1976 to 2006 that we judged worthy of consideration, but that had not been nominated at the meeting. Conclusions: The meeting did not represent an objective selection process, but it did demonstrate that the past 30 years have yielded major new discoveries in nutrition and health.
- Open Access
- 12 September 2007
- Published by Springer Nature in BMC Microbiology
- Vol. 7 (1) , 84
Salmonella induces prominent gene expression in the rat colon
Background: Salmonella enteritidisis suggested to translocate in the small intestine.In vivoit induces gene expression changes in the ileal mucosa and Peyer's patches. Stimulation ofSalmonellatranslocation by dietary prebiotics fermented in colon suggests involvement of the colon as well. However, effects ofSalmonellaon colonic gene expressionin vivoare largely unknown. We aimed to characterize time dependentSalmonella-induced changes of colonic mucosal gene expression in rats using whole genome microarrays. For this, rats were orally infected withSalmonella enteritidisto mimic a foodborne infection and colonic gene expression was determined at days 1, 3 and 6 post-infection (n = 8 rats per time-point). As fructo-oligosaccharides (FOS) affect colonic physiology, we analyzed colonic mucosal gene expression of FOS-fed versus cellulose-fed rats infected withSalmonellain a separate experiment. Colonic mucosal samples were isolated at day 2 post-infection.Results: Salmonellaaffected transport (e.g. Chloride channel calcium activated 6, H+/K+transporting Atp-ase), antimicrobial defense (e.g. Lipopolysaccharide binding protein, Defensin 5 and phospholipase A2), inflammation (e.g. calprotectin), oxidative stress related genes (e.g. Dual oxidase 2 and Glutathione peroxidase 2) and Proteolysis (e.g. Ubiquitin D and Proteosome subunit beta type 9). Furthermore,Salmonellatranslocation increased serum IFNγ and many interferon-related genes in colonic mucosa. The gene most strongly induced bySalmonellainfection was Pancreatitis Associated Protein (Pap), showing >100-fold induction at day 6 after oral infection. Results were confirmed by Q-PCR in individual rats. Stimulation ofSalmonellatranslocation by dietary FOS was accompanied by enhancement of theSalmonella-induced mucosal processes, not by induction of other processes.Conclusion: We conclude that the colon is a target tissue forSalmonella, considering the abundant changes in mucosal gene expression.
- 12 September 2007
- Published by Springer Nature in BMC Microbiology
- Vol. 7 (1) , 84
Open AccessSalmonella induces prominent gene expression in the rat colon
Background: Salmonella enteritidisis suggested to translocate in the small intestine.In vivoit induces gene expression changes in the ileal mucosa and Peyer's patches. Stimulation ofSalmonellatranslocation by dietary prebiotics fermented in colon suggests involvement of the colon as well. However, effects ofSalmonellaon colonic gene expressionin vivoare largely unknown. We aimed to characterize time dependentSalmonella-induced changes of colonic mucosal gene expression in rats using whole genome microarrays. For this, rats were orally infected withSalmonella enteritidisto mimic a foodborne infection and colonic gene expression was determined at days 1, 3 and 6 post-infection (n = 8 rats per time-point). As fructo-oligosaccharides (FOS) affect colonic physiology, we analyzed colonic mucosal gene expression of FOS-fed versus cellulose-fed rats infected withSalmonellain a separate experiment. Colonic mucosal samples were isolated at day 2 post-infection.Results: Salmonellaaffected transport (e.g. Chloride channel calcium activated 6, H+/K+transporting Atp-ase), antimicrobial defense (e.g. Lipopolysaccharide binding protein, Defensin 5 and phospholipase A2), inflammation (e.g. calprotectin), oxidative stress related genes (e.g. Dual oxidase 2 and Glutathione peroxidase 2) and Proteolysis (e.g. Ubiquitin D and Proteosome subunit beta type 9). Furthermore,Salmonellatranslocation increased serum IFNγ and many interferon-related genes in colonic mucosa. The gene most strongly induced bySalmonellainfection was Pancreatitis Associated Protein (Pap), showing >100-fold induction at day 6 after oral infection. Results were confirmed by Q-PCR in individual rats. Stimulation ofSalmonellatranslocation by dietary FOS was accompanied by enhancement of theSalmonella-induced mucosal processes, not by induction of other processes.Conclusion: We conclude that the colon is a target tissue forSalmonella, considering the abundant changes in mucosal gene expression.